Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWSulconazole is an azole antifungal that is active against dermatophyte fungal species, including isolates of various Candida species.1 It acts as a non-specific inhibitor of styrene metabolism by cytochrome P450 (CYP450) enzymes, with Ki values ranging from 0.008 to 3.5 µM against various CYP450 isoforms in human lymphoblast microsomes in vitro.2,3 In rat spleen microsomes, it inhibits the activity of heme oxygenase 1 with an IC50 value of 1.1 µM.4 Sulconazole inhibits DNA damage induced by the metabolism of styrene by bacterial CYP450cam with a Ki value of 204.2 μM in an electrochemical biosensor model.2 Formulations containing sulconazole have been used for the treatment of fungal infections.
WARNING This product is not for human or veterinary use.
1. Antifungal relative inhibition factors: BAY 1–9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14–4767/002, sulconazole, terconazole and vibunazole (BAY n-
2. Characterizing metabolic inhibition using electrochemical enzyme/DNA biosensors. Anal. Chem. 81(2), 716-724 (2009).
3. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab. Dispos. 30(3), 314-318 (2002).
4. Inhibition of the enzymatic activity of heme oxygenases by azole-